Mission
Adjuvants are key components for enhancing the efficacy of several vaccines by improving immune responses and reducing antigen amounts per dose of vaccine.
VFI’s mission is to develop clinically-relevants adjuvants for benefit of the vaccine community and Global Health.
On a not-for-profit basis, VFI facilitates knowledge transfer by providing adjuvant know-how and formulation expertise for prophylactic and therapeutic, human and veterinary vaccines. VFI is funded by renowned stakeholders in the field, such as the Bill & Melinda Gates Foundation and the European Commission.
Activities
VFI develops a range of adjuvants and provides expertise for the optimization of vaccine formulations suitable for preclinical and clinical testing.
VFI shares its expertise with numerous leading European and International institutions in the field of vaccines and adjuvants. Among other activities, VFI leads the Adjuvants and Formulations platform of the Global Health Discovery Collaboaratory. VFI is also partner of TRANSVAC and ISIDORE, both leading European vaccine infrastructure dedicated on accelerating the development of vaccines.
VFI global access policy
The Vaccine Formulation Institute is a not-for-profit organization dedicated to improving global health by developing vaccine adjuvants suitable for distribution to the entire vaccine community, including the people most in need in resource-challenged economies.
VFI is committed to Global Open Access and/or non-exclusivity for the outlicensing of our technologies. Such principles are in line with those outlined in policies of our funders, including the Bill and Melinda Gates Foundation Open Access and Humanitarian License policies.
VFI is a not-for-profit company located in Switzerland and our vision is that the adjuvants we develop will be EMEA/FDA-approved and used in vaccination programs targeted to people who have until now had a reduced opportunity to receive effective vaccines.
In VFI’s role as an adjuvant developer, VFI will not knowingly infringe the rights of any validly granted patent. We take pride in our cutting edge research and open dialogue with collaborators.